Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

74 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Transiently achieved very low LDL-cholesterol levels by statin and alirocumab after acute coronary syndrome are associated with cardiovascular risk reduction: the ODYSSEY OUTCOMES trial.
Schwartz GG, Szarek M, Bhatt DL, Bittner VA, Bujas-Bobanovic M, Diaz R, Fazio S, Fras Z, Goodman SG, Harrington RA, Jukema JW, Manvelian G, Pordy R, Ray KK, Scemama M, White HD, Steg PG; ODYSSEY OUTCOMES Investigators. Schwartz GG, et al. Among authors: bittner va. Eur Heart J. 2023 Mar 5;44(16):1408-17. doi: 10.1093/eurheartj/ehad144. Online ahead of print. Eur Heart J. 2023. PMID: 36879424 Free PMC article.
Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment.
Schwartz GG, Szarek M, Bittner VA, Bhatt DL, Diaz R, Goodman SG, Jukema JW, Loy M, Manvelian G, Pordy R, White HD, Steg PG; ODYSSEY OUTCOMES Committees and Investigators. Schwartz GG, et al. Among authors: bittner va. Diabetes Care. 2021 May;44(5):1219-1227. doi: 10.2337/dc20-2842. Epub 2021 Mar 15. Diabetes Care. 2021. PMID: 33722880 Free PMC article.
Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients.
Nissen SE, Lincoff AM, Brennan D, Ray KK, Mason D, Kastelein JJP, Thompson PD, Libby P, Cho L, Plutzky J, Bays HE, Moriarty PM, Menon V, Grobbee DE, Louie MJ, Chen CF, Li N, Bloedon L, Robinson P, Horner M, Sasiela WJ, McCluskey J, Davey D, Fajardo-Campos P, Petrovic P, Fedacko J, Zmuda W, Lukyanov Y, Nicholls SJ; CLEAR Outcomes Investigators. Nissen SE, et al. N Engl J Med. 2023 Apr 13;388(15):1353-1364. doi: 10.1056/NEJMoa2215024. Epub 2023 Mar 4. N Engl J Med. 2023. PMID: 36876740 Clinical Trial.
Lipoprotein(a) and the Effect of Alirocumab on Revascularization After Acute Coronary Syndrome.
Steg PG, Szarek M, Valgimigli M, Islam S, Zeiher AM, Bhatt DL, Bittner VA, Chiang CE, Diaz R, Goodman SG, Gotcheva N, Harrington RA, Jukema JW, Kim HS, Kim SH, Morais J, Pordy R, Scemama M, White HD, Schwartz GG; ODYSSEY OUTCOMES Investigators. Steg PG, et al. Among authors: bittner va. Can J Cardiol. 2023 Oct;39(10):1315-1324. doi: 10.1016/j.cjca.2023.04.018. Epub 2023 Apr 26. Can J Cardiol. 2023. PMID: 37116789 Free article.
Estimated number and percentage of US adults with atherosclerotic cardiovascular disease recommended add-on lipid-lowering therapy by the 2018 AHA/ACC multi-society cholesterol guideline.
Alanaeme CJ, Bittner V, Brown TM, Colantonio LD, Dhalwani N, Jones J, Kalich B, Exter J, Jackson EA, Levitan EB, Poudel B, Wang Z, Woodward M, Muntner P, Rosenson RS. Alanaeme CJ, et al. Am Heart J Plus. 2022 Sep;21:100201. doi: 10.1016/j.ahjo.2022.100201. Epub 2022 Aug 27. Am Heart J Plus. 2022. PMID: 37168932 Free PMC article.
Safety Of The Pcsk9 Inhibitor Alirocumab: insights From 47,296 Patient-Years Of Observation.
Goodman SG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Harrington RA, Jukema JW, White HD, Zeiher AM, Manvelian G, Pordy R, Poulouin Y, Stipek W, Garon G, Schwartz GG. Goodman SG, et al. Among authors: bittner va. Eur Heart J Cardiovasc Pharmacother. 2024 Apr 24:pvae025. doi: 10.1093/ehjcvp/pvae025. Online ahead of print. Eur Heart J Cardiovasc Pharmacother. 2024. PMID: 38658193
Comparison of Change in Lipoprotein(a) Mass and Molar Concentrations by Alirocumab and Risk of Subsequent Cardiovascular Events in ODYSSEY OUTCOMES.
Szarek M, Reijnders E, Steg PG, Jukema JW, Schwertfeger M, Bhatt DL, Bittner VA, Diaz R, Fazio S, Garon G, Goodman SG, Harrington RA, White HD, Zeiher AM, Cobbaert C, Schwartz GG. Szarek M, et al. Among authors: bittner va. Eur J Prev Cardiol. 2024 Mar 19:zwae110. doi: 10.1093/eurjpc/zwae110. Online ahead of print. Eur J Prev Cardiol. 2024. PMID: 38501249 No abstract available.
Long-Term Efficacy, Safety, and Tolerability of Alirocumab in 8242 Patients Eligible for 3 to 5 Years of Placebo-Controlled Observation in the ODYSSEY OUTCOMES Trial.
Goodman SG, Steg PG, Poulouin Y, Bhatt DL, Bittner VA, Diaz R, Garon G, Harrington RA, Jukema JW, Manvelian G, Stipek W, Szarek M, White HD, Schwartz GG; ODYSSEY OUTCOMES Investigators. Goodman SG, et al. Among authors: bittner va. J Am Heart Assoc. 2023 Sep 19;12(18):e029216. doi: 10.1161/JAHA.122.029216. Epub 2023 Sep 13. J Am Heart Assoc. 2023. PMID: 37702079 Free PMC article. Clinical Trial. No abstract available.
74 results